Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.

Schneider A, Corona A, Spöring I, Jordan M, Buchholz B, Maccioni E, Di Santo R, Bodem J, Tramontano E, Wöhrl BM.

Nucleic Acids Res. 2016 Mar 18;44(5):2310-22. doi: 10.1093/nar/gkw060. Epub 2016 Feb 4.

2.

Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.

Nakamura A, Tamura N, Yasutake Y.

Acta Crystallogr F Struct Biol Commun. 2015 Nov;71(Pt 11):1384-90. doi: 10.1107/S2053230X15017896. Epub 2015 Oct 23.

3.

A farewell to didanosine: harm reduction and cost savings by eliminating use of didanosine.

Dziuban EJ, Raizes E, Koumans EH.

Int J STD AIDS. 2015 Oct;26(12):903-6. doi: 10.1177/0956462414554433. Epub 2014 Oct 2.

4.

A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.

Kolomeets AN, Varghese V, Lemey P, Bobkova MR, Shafer RW.

AIDS. 2014 Nov 13;28(17):F1-8. doi: 10.1097/QAD.0000000000000485.

5.

Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.

Abram ME, Ferris AL, Das K, Quinoñes O, Shao W, Tuske S, Alvord WG, Arnold E, Hughes SH.

J Virol. 2014 Jul;88(13):7589-601. doi: 10.1128/JVI.00302-14. Epub 2014 Apr 23.

6.

Transmitted HIV drug resistance in treatment-naive Romanian patients.

Temereanca A, Ene L, Mehta S, Manolescu L, Duiculescu D, Ruta S.

J Med Virol. 2013 Jul;85(7):1139-47. doi: 10.1002/jmv.23572. Epub 2013 Apr 16.

7.

A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Shafer RW, Dupnik K, Winters MA, Eshleman SH.

HIV Seq Compend. 2001;2001:1-51. No abstract available.

8.

Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.

Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, Burke DH, Johnson M, Ding S, Zheng YM, Liu SL, Kodama E, Delviks-Frankenberry KA, Pathak VK, Mitsuya H, Parniak MA, Singh K, Sarafianos SG.

Nucleic Acids Res. 2012 Jan;40(1):345-59. doi: 10.1093/nar/gkr694. Epub 2011 Sep 8.

9.

The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.

Mbisa JL, Gupta RK, Kabamba D, Mulenga V, Kalumbi M, Chintu C, Parry CM, Gibb DM, Walker SA, Cane PA, Pillay D.

Retrovirology. 2011 May 11;8:31. doi: 10.1186/1742-4690-8-31.

10.

4'-C-methyl-2'-deoxyadenosine and 4'-C-ethyl-2'-deoxyadenosine inhibit HIV-1 replication.

Vu BC, Boyer PL, Siddiqui MA, Marquez VE, Hughes SH.

Antimicrob Agents Chemother. 2011 May;55(5):2379-89. doi: 10.1128/AAC.01290-10. Epub 2011 Feb 22.

11.

K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism.

Hachiya A, Kodama EN, Schuckmann MM, Kirby KA, Michailidis E, Sakagami Y, Oka S, Singh K, Sarafianos SG.

PLoS One. 2011 Jan 13;6(1):e16242. doi: 10.1371/journal.pone.0016242.

12.

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Singh K, Marchand B, Kirby KA, Michailidis E, Sarafianos SG.

Viruses. 2010 Feb 11;2(2):606-638.

13.

Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.

Matamoros T, Nevot M, Martínez MA, Menéndez-Arias L.

J Biol Chem. 2009 Nov 20;284(47):32792-802. doi: 10.1074/jbc.M109.038885. Epub 2009 Sep 29.

14.

Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.

Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS.

J Infect Dis. 2009 May 1;199(9):1323-6. doi: 10.1086/597802.

15.
16.

Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

Waléria-Aleixo A, Martins AN, Arruda MB, Brindeiro RM, Da-Silva RM, Nobre FF, Greco DB, Tanuri A.

Antimicrob Agents Chemother. 2008 Dec;52(12):4497-502. doi: 10.1128/AAC.00820-08. Epub 2008 Oct 6.

17.

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Shafer RW, Schapiro JM.

AIDS Rev. 2008 Apr-Jun;10(2):67-84. Review.

18.

Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD.

Antimicrob Agents Chemother. 2008 Jan;52(1):329-32. Epub 2007 Oct 29.

19.

Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol.

Karlsson AC, Chapman JM, Heiken BD, Hoh R, Kallas EG, Martin JN, Hecht FM, Deeks SG, Nixon DF.

J Virol. 2007 Oct;81(20):11543-8. Epub 2007 Aug 1.

Supplemental Content

Support Center